Wire · opportunities
Physician Views Preview: Do myeloma specialists see BMS's newly approved Zenbexus as ...
◆ Sectors
◆ Geography
◆ Source
◆ Verified
Fusion42 · 23 August 2026 · Fusion42 review
The FDA granted accelerated approval to Bristol Myers Squibb's Zenbexus (iberdomide), a new class of cereblon E3 ligase modulators for multiple myeloma, based on minimal residual disease-negative complete response. The drug is authorized in combination with Johnson & Johnson's Darzalex Faspro and dexamethasone for relapsed or refractory multiple myeloma after prior therapy.
This Wire brief sits within Fusion42's coverage of Biotech.
◆ ◆ The Wire takeaway
Zenbexus's approval based on MRD-negative response resets treatment benchmarks in multiple myeloma, so you should engage clinicians now to shape early adoption and usage patterns. The emphasis on MRD-negativity creates a new efficacy standard your product must meet or surpass.
◆ Coverage
1 source · 23 Aug 2026
◆ Related on Wire
◆ Topics